Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00066144 · ClinicalTrials.gov registry record · Phase 2

Use of Black Cohosh and Red Clover for the Relief of Menopausal Symptoms

A Phase 2 study of Menopause and Hot Flashes, sponsored by National Center for Complementary and Integrative Health (NCCIH).

Completed
Registry status
Phase 2
Development phase
112
Enrollment target
1
Study location

NCT00066144: Completed Phase 2 study of Menopause and Hot Flashes, sponsored by National Center for Complementary and Integrative Health (NCCIH).

NCT00066144 is a Phase 2 study of Menopause and Hot Flashes that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 112 participants, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00066144, a Phase 2 study of Menopause and Hot Flashes, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).

COMPLETED
Registry status
Phase 2
Development phase
112 participants
Enrollment target
1
Study location

Study Summary

This Phase II study, a follow-up to a Phase I trial in normal volunteers, will determine the efficacy of black cohosh and red clover for the relief of menopausal symptoms. It will also assess the safety of chronic dosing (1 year) by evaluating uterine (endometrial biopsies), breast (mammography), and hematology parameters (CBC and chemistry lab values) at baseline and 1 year.

Conditions Studied

Interventions

  • DRUG Cimicifuga racemosa
  • DRUG Trifolium pratense
  • DRUG Black cohosh
  • DRUG Red clover

Study Locations (1)

Illinois

  • University of Illinois at Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2003-04
Est. Completion 2006-04
Phase Phase 2

What the finished NCT00066144 record still lists

NCT00066144 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Menopause appearing as the primary indexed condition, and to 4 interventions - of which Cimicifuga racemosa is the first listed.

NCT00066144 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT00066144 about?

NCT00066144 is a clinical study titled "Use of Black Cohosh and Red Clover for the Relief of Menopausal Symptoms". This Phase II study, a follow-up to a Phase I trial in normal volunteers, will determine the efficacy of black cohosh and red clover for the relief of menopausal symptoms. It will also assess the safety of chronic dosing (1 year) by evaluating uterine (endometrial biopsies), breast (mammography), an...

What is the current status of trial NCT00066144?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2003-04. Estimated completion is 2006-04.

What conditions does trial NCT00066144 study?

This clinical trial studies the following conditions: Menopause, Hot Flashes.

What interventions are being tested in trial NCT00066144?

The interventions under investigation include: Cimicifuga racemosa (DRUG), Trifolium pratense (DRUG), Black cohosh (DRUG), Red clover (DRUG).

Who is sponsoring clinical trial NCT00066144?

This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00066144 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Menopause

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00066144's enrollment target sits among peer trials

112 16th of 54 higher than 39 of 54 other Menopause trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04511013 · 112 participants · Phase 2

    A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

  • NCT04551560 · 112 participants · NA

    Stress and Congestive Heart Failure

  • NCT04872166 · 112 participants · Phase 1

    A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

  • NCT05024773 · 112 participants · Phase 3

    Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00066144, the US trial registry maintained by the National Library of Medicine. NCT00066144 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.